Philipp Mueller

Philipp Mueller is an Executive Director and Investment Manager on the Therapeutics Investment Team at the Boehringer Ingelheim Venture Fund, based in Biberach an der Riß, Germany. Before joining the venture fund in 2020, he spent four years in research and development at Boehringer Ingelheim, serving as a Principal Scientist and later as a Senior Principal Scientist. Previously, he worked as the Head of the Cancer Immunology and Immunotherapy Laboratory at the University of Basel, where he also earned his doctorate in biochemistry. In his current role, Mueller holds board director seats at several European biotechnology startups, including Asgard Therapeutics SA and SwitchKine AG. He also serves on the selection committee for INCATE, evaluating new antimicrobial resistance technologies. His primary investment focus centers on European life sciences innovations, targeting immuno-oncology, translational research, and infectious disease drug development.